

Lung Epithelial Regnase-1 Dampens Local Immune Response but Does Not Worsen Susceptibility to *Klebsiella pneumoniae*

Becky Lin,* Li Fan,[†] Shatterra Jackson,* Aidan R. Matunis,* Dequan Lou,[†] Kong Chen,[†] and Giralдина Trevejo-Nuñez*

*Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA; and [†]Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

ABSTRACT

Klebsiella pneumoniae (KP) presents a global health threat, leading to significant morbidity and mortality due to its multidrug-resistant profile and the limited availability of therapeutic options. To eliminate KP lung infection, the host initiates a robust inflammatory response. One of the host's mechanisms for mitigating excessive inflammation involves the RNA-binding protein regnase-1 (Reg1, MCPIP1, or ZC3H12A). Reg1 has an RNA binding domain that recognizes stem-loop structures in the 3' untranslated region of various proinflammatory transcripts, leading to mRNA decay. However, excessive suppression of inflammation by Reg1 results in suboptimal KP control. Reg1 deficiency within the nonhematopoietic compartment confers resistance to KP in the lung. Given that lung epithelium is crucial for KP resistance, we hypothesized that selective deletion of Reg1 in lung epithelial cells might enhance proinflammatory signals, leading to a better control of KP. Our transcriptomic analysis of epithelial cells in KP-infected wild-type mice revealed the presence of three distinct alveolar type 2 cell (AT2) subpopulations (conventional, inflammatory, and cycling) and enrichment of Reg1 in inflammatory AT2 cells. We conditionally deleted Reg1 in lung AT2 cells (Δ Reg1), which amplified the local inflammatory response in the lung and increased macrophage cell numbers compared with controls. However, when Δ Reg1 mice were subjected to KP infection, there were no significant differences in bacterial burden or survival compared with controls. These findings suggest that the local inflammatory response enhanced by Reg1 deletion in AT2 cells is insufficient to control KP infection. *ImmunoHorizons*, 2024, 8: 89–96.

INTRODUCTION

Klebsiella pneumoniae (KP) accounts for 8–10% of healthcare-associated infections and ranks as the third leading cause of healthcare-associated pneumonia in the United States (1, 2), presenting a significant medical challenge due to its multidrug resistance profile. Although most multidrug-resistant KP strains are hospital acquired and affect immunosuppressed patients, there is a growing awareness of hypervirulent KP strains, which are community-acquired and infect both immunocompetent and

immunosuppressed individuals. Historically, hypervirulent KP strains were documented predominantly in Asia. However, more recently, there has been increased recognition of these KP strains in Europe and the United States, with a prevalence of 2.6–3.7% (3). Moreover, some of these hypervirulent KP strains have acquired multidrug-resistant genes, posing a concerning threat (4–7). Consequently, there is a pressing scientific need to expand our understanding of host–pathogen interactions and explore strategies to enhance the immune system's ability to counteract severe KP infections.

Received for publication September 25, 2023. Accepted for publication December 22, 2023.

Address correspondence and reprint requests to: Dr. Giralдина Trevejo-Nuñez, University of Pittsburgh, 200 Lothrop Street, E1056 Biomedical Science Tower, Pittsburgh, PA 15213. E-mail address: giralдина.trevejo@pitt.edu

ORCIDs: 0000-0003-4604-5389 (B.L.); 0009-0002-6112-8465 (A.R.M.); 0000-0002-9770-763X (G.T.-N.).

This work was supported by National Institutes of Health Grants HL135476, HL154231, and AI153549 (to G.T.-N.) and the University of Pittsburgh, Department of Medicine K Awardee to R Advancement Training (KARAT) award.

The sequences presented in this article have been submitted to the Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248351>) under accession number GSE248351.

Abbreviations used in this article: AT2, alveolar type 2 cell; KO, knockout; KP, *Klebsiella pneumoniae*; qPCR, quantitative PCR; UTR, untranslated region; WT, wild type.

The online version of this article contains supplemental material.

This article is distributed under the terms of the [CC BY-NC 4.0 Unported license](https://creativecommons.org/licenses/by-nc/4.0/).

Copyright © 2024 The Authors

<https://doi.org/10.4049/immunohorizons.2300082>

ImmunoHorizons is published by The American Association of Immunologists, Inc.

During pneumonia, the host initiates a robust inflammatory response for successful pathogen eradication, but this response can come at the cost of tissue injury. During inflammation, the host activates negative feedback mechanisms to mitigate inflammatory collateral damage, such as the endoribonuclease regnase-1 (Reg1, *Zc3h12a*, MCPIP1). Reg1 is an RNA-binding protein that identifies and degrades several proinflammatory mRNAs, such as *Il1b*, *Il12b*, *Il6*, *Nfkbiz*, and its mRNA *Zc3h12a*. Additionally, Reg1 serves as a negative feedback regulator of LPS and IL-17 signal transduction, both essential pathways for KP eradication. Consequently, increased Reg1 can hinder the control of KP infection by excessive suppression of proinflammatory pathways.

Our previous findings in bone marrow chimeras using global heterozygous mice demonstrated that Reg1 deficiency in hematopoietic and nonhematopoietic compartments confers resistance to KP (8). Building on this prior work, we investigated the role of Reg1 in epithelial cells, precisely alveolar type 2 cells (AT2), to control KP infection.

Different AT2 cell clusters start segregating during KP infection, including conventional, inflammatory, and cycling AT2 cells. *Reg1* (*Zc3h12a*) exhibited the highest expression in inflammatory AT2 cells. As a result, we assessed Reg1 in AT2 cells by crossing *Reg1^{flox/flox}* mice with *Sftpc^{CreERT2}* mice (referred to as Δ Reg1 in this paper) to conditionally delete *Reg1* in AT2 cells. Furthermore, Reg1 deletion in AT2 cells triggered local proinflammatory cytokines and increased alveolar macrophage numbers 48 h after KP infection. However, these enhanced proinflammatory epithelial signals from Δ Reg1 mice did not impact KP bacterial burden or survival, suggesting that Reg1 deletion in AT2 cells alone is insufficient for controlling KP lung infection.

MATERIALS AND METHODS

Mice

Zc3h12a^{flox/flox} mice are under a material transfer agreement from the University of Central Florida (Orlando, FL). *Sftpc^{CreERT2}* (028054) and *Rosa26^{mT/mG}* (007676) mice were from The Jackson Laboratory. Mice were 8–12 wk old, and both sexes were used. All animal studies were approved by the institutional animal care and use committee of the University of Pittsburgh.

Bacterial infections

KP American Type Culture Collection strain 43816 was grown in Luria-Bertani broth to reach the early log phase. We administered $1\text{--}2 \times 10^3$ CFU/mouse in PBS by deep oropharyngeal aspiration. Where indicated, tamoxifen was dissolved in corn oil and administered i.p. for 4 d and then rested for 7–10 d before induction of infection (dose, 2 mg/mouse).

Bacterial burden, mRNA, and protein analysis

Tissues were homogenized in PBS, and CFU levels were assessed by serial dilution plating. Lung tissues were homogenized in TRIzol (Invitrogen) and subjected to quantitative PCR (qPCR) with SYBR Green probes. Threshold cycle values were normalized to *Gapdh*. ELISA kits were from eBioscience (Thermo Fisher

Scientific) and R&D Systems. Abs used for Western blots were ZC3H12A (GeneTex; GTX110807), I κ B ζ (Cell Signaling Technology; 93726 and 9244), and β -actin (Abcam; ab49900).

Lung tissue processing

To extract lung epithelial cells, murine lungs were perfused with 10 ml of PBS, injected with dispase (2.5 ml/lung), followed by lung extraction and incubation in a water bath for 5 min. Lungs were homogenized in OctoMACS for 5 min. Cell suspensions were passed through 70- μ m and a 40- μ m cell strainers and treated with RBC lysis buffer to generate a single-cell suspension. Epithelial cells were obtained by negative selection by staining cells for CD45, LyG, CD11b, CD11c, Siglec-F, Ly6C, and MHC class II. Negative selection fractions were stained for CD45, CD31, and Epcam and sorted by flow cytometry (CD45⁻CD31⁻Epcam⁺) for single-cell RNA sequencing.

For lung hematopoietic cells, after perfusion with PBS, lungs were digested with collagenase and DNase, passed through a 70- μ m strainer, and treated with RBC lysis buffer to generate a single-cell suspension. Abs were from eBioscience, BD Biosciences, or BioLegend. Data were acquired on an LSRFortessa and analyzed with FlowJo software.

Deletion of REG1 (ZC3H12A) in a human bronchial epithelial cell line

The deletion of *ZC3H12A* was performed by Synthego using CRISPR-Cas9. Human bronchial epithelial (HBE3-KT-ATCC) cells were electroporated with Cas9 and a *ZC3H12A*-specific sgRNA (5'-CACCACCCCGCGGGACUAGA-3'). Isogenic negative control cells were electroporated only with Cas9. The cells were expanded to get a knockout (KO) cell pool. Clonal *ZC3H12A*-KO cell lines were generated by limiting dilution. Genomic DNA from monoclonal populations was verified by PCR and Sanger sequencing using *ZC3H12A*-specific primers (forward, 5'-GCCCT-GGAAGTGCAGATGAA-3'; reverse, 5'-CTTCTCCAGCCCACCAG-AG-3'). The sequencing results were analyzed using the interactive Inference of CRISPR Edits results (www.ice.synthego.com).

Single-cell RNA sequencing

The lungs were removed from four mice 48 h after KP infection. The lungs were processed as above and enumerated by Cellometer2000 right before loading onto a 10 \times Chromium controller for cell capture (targeting 5000 cells per sample) using the Chromium Single Cell Immune Profiling v2 Dual index kits (catalog no. 1000263). Libraries for gene expression were constructed following protocols from 10 \times Genomics. Final libraries were quality controlled by Agilent TapeStation, then sequenced on an Illumina NovaSeq 6000, targeting 50,000 reads per cell. Sequencing data were processed with Cell Ranger 7.0 before downstream analysis using Seurat.

Single-cell RNA-sequencing data analysis

Single-cell RNA-sequencing analysis was performed using Seurat 4.0 with R (version 4.1.1). Poor-quality droplets were excluded

from subsequent analysis if a deficient number of the genes and a high percentage of mitochondrial genes were detected. Differential gene expression was performed using a nonparametric Wilcoxon rank-sum test. The results were adjusted for multiple comparisons using the Bonferroni correction. The single-cell sequencing data were deposited in the Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248351>).

Statistical analysis

Data were analyzed using Prism (GraphPad Software). Data were analyzed by log-rank test, one-way ANOVA, and Student *t* test as indicated. Each symbol represents one mouse or one well of stimulated cells unless otherwise indicated.

RESULTS

Differential expression of *Reg1* in lung epithelial cells during KP infection


We analyzed single-cell transcriptome data from wild-type (WT) mice to gain insight into *Reg1* expression within lung epithelial cells during KP infection. *Reg1* was highly expressed in AT2 cells

compared with ciliated, secretory, and type 1 alveolar epithelial cells. Furthermore, after KP infection, AT2 cells clustered in different groups: conventional AT2 cells (c-AT2) with enriched canonical epithelial genes, inflammatory AT2 cells (i-AT2) with enhanced proinflammatory genes, and proliferative AT2 cells (p-AT2) with associated cell cycle genes (Fig. 1A, 1B). Among these three groups, *Reg1* was mainly enriched in inflammatory AT2 cells (i-AT2) (Fig. 1C). Therefore, *Reg1* (*Zc3h12a*) segregates with the inflammatory AT2 cluster during KP infection.

Conditional deletion of *Reg1* in alveolar type 2 epithelial cells

Reg1 is ubiquitously expressed. However, its function in the lung structural compartment needs to be better characterized. Because *Reg1* was enriched in AT2 cells during KP infection, we conditionally deleted *Reg1* in AT2 cells by breeding *Reg1*^{flx/flx} with *Sftpc*^{Cre ERT2+} or *Sftpc*^{Cre ERT2-} mice (referred to as Δ *Reg1* or WT *Reg1* in this paper). Moreover, to evaluate the specificity of *Sftpc*^{Cre ERT2} expression in AT2 cells, Δ *Reg1* mice were crossed with a *Rosa26*^{mT/mG} reporter mouse, a cell membrane-targeted, two-color fluorescent Cre-reporter allele. When recombined, Cre recombinase-expressing cells revealed GFP (mG) replacing the red fluorescence Td Tomato (mT). An average of 78.7% of AT2

FIGURE 1. Regnase 1 (*Reg1/Zc3h12a*) is expressed in inflammatory AT2 cells (i-AT2). CD45⁻CD31⁻EPCAM⁺ cells were identified by single-cell RNA sequencing. (A) Clusters of AT2 cells: conventional AT2 (c-AT2), inflammatory AT2 (i-AT2), and proliferative AT2 (p-AT2). Analysis visualized by Uniform Manifold Approximation and Projection (UMAP) and assigned different colors. (B) Dot plot showing selected canonical genes in each cluster of alveolar epithelial cells. (C) *Reg1* (*Zc3h12a*) expression in each cluster of AT2 cells.



sorted cells ($CD45^{-}CD31^{-}Epcam^{+}MHCII^{hi}$) were GFP^{+} after tamoxifen administration, and the average Cre recombination of the *Reg1* floxed region in these GFP^{+} AT2 cells was 87.2% (Fig. 2A). Furthermore, *Reg1* (*Zc3h12a*) expression in sorted epithelial cells ($CD45^{-}CD31^{-}Epcam^{+}$) was significantly downregulated in $\Delta Reg1$ compared with *WT Reg1* mice (Fig. 2B). Thus, *Reg1* conditional deletion in AT2 cells has adequate recombination efficiency.

***Reg1* deletion in alveolar type 2 cells and epithelial cells increases local $I\kappa B\zeta$ expression**

Reg1 degrades proinflammatory transcripts through a stem-loop sequence in its 3' untranslated region (UTR), and *Reg1* negatively regulates *Nfkbiz*, which encodes the transcriptional regulator $I\kappa B\zeta$ (9). As such, we hypothesized that *Reg1* deletion in AT2 cells would increase the expression of *Nfkbiz*. $I\kappa B\zeta$ was increased in sorted epithelial cells ($CD45^{-}CD31^{-}Epcam^{+}$) from $\Delta Reg1$ mice compared with *WT Reg1* mice at 48 h after KP infection (Fig. 3A).

Moreover, *REG1*-deleted human bronchial epithelial cells ($\Delta REG1$) significantly expressed $I\kappa B\zeta$ compared with *WT REG1* after KP infection. Concomitantly, other targets known to be degraded by *REG1* were increased in $\Delta REG1$ compared with *WT REG1* cells, such as IL-1 β , GM-CSF, and *IL6* (Fig. 3B, 3C). Thus, epithelial *REG1* controls $I\kappa B\zeta$ expression during KP infection.

***Reg1* deletion in alveolar type 2 cells increases alveolar macrophage numbers**

To assess the impact of *Reg1* deletion in AT2 cells on lung hematopoietic cells, we assessed *Reg1* target proinflammatory genes. *Nfkbiz* and *Il6*, known *Reg1* targets, were increased in $\Delta Reg1$ murine lungs compared with controls at 48 h after KP

infection. However, there were no significant differences in *Il1b*, *Tnf*, or chemokines such as *Cxcl1*, *Cxcl5*, and *Ccl2* (Fig. 4A). Neutrophils, inflammatory monocytes, and $CD11b^{+}$ dendritic cells were similarly recruited into the infected lung of *WT Reg1* and $\Delta Reg1$ mice. Unexpectedly, alveolar macrophage numbers were increased in $\Delta Reg1$ mice compared with controls at 48 h after KP infection (Fig. 4B). Lung permeability did not account for these findings, because total lung protein and epithelial tight junction expression (*Cldn4*, *Cldn5*) were similar between *WT Reg1* and $\Delta Reg1$ mice (Supplemental Fig. 1A, 1B). In addition, type I IFN-dependent genes and IFN- β were not affected by the deletion of *Reg1* in AT2 cells (Supplemental Fig. 1D, 1E). Thus, selective *Reg1* deletion in AT2 cells induces higher alveolar macrophage numbers at 48 h after KP infection.

***Reg1* deletion in alveolar type 2 cells does not impact survival upon KP lung infection**

Because *Reg1* deletion in AT2 cells increased *Nfkbiz* and correlated with increased host alveolar macrophages, we assessed bacterial burden and survival. Bacterial burden in the lung and spleen were similar between *WT Reg1* and $\Delta Reg1$ mice (Fig. 5A, 5B). Furthermore, there was no difference in survival up to 7 d after KP infection or significant weight loss changes between *WT Reg1* and $\Delta Reg1$ mice (Fig. 5C, 5D). Thus, *Reg1* deletion in AT2 cells is insufficient to ameliorate KP lung infection.

DISCUSSION

Reg1, an RNA-binding protein, is ubiquitously expressed and downregulates inflammation by degrading translationally active transcripts such as *Il1b*, *Il12b*, *Nfkbiz*, and *Il6*, among




FIGURE 2. *Reg1* is efficiently recombined in AT2 cells.

WT Reg1 and $\Delta Reg1$ mice were crossed with *Rosa26^{MT/mG}* reporter mice. (A) Lung epithelial cells ($CD45^{-}CD31^{-}Epcam^{+}$) were assessed by flow cytometry. $Epcam^{+}MHCII^{hi}GFP^{+}$ (AT2 GFP^{+}) and $Epcam^{+}MHCII^{hi}TdTomato^{+}$ (AT2 TdT^{+}) were sorted and evaluated for *Reg1* (*Zc3h12a*) recombination efficiency by qPCR. (B) Lung epithelial cells ($CD45^{-}CD31^{-}Epcam^{+}$) from $\Delta Reg1$ and *WT Reg1* mice were sorted and assessed for *Zc3h12a* expression by qPCR. * $p < 0.05$, unpaired *t* test.




FIGURE 3. Reg1 controls I κ B ζ in epithelial cells.

WT Reg1 and $\Delta Reg1$ mice were infected with KP and sacrificed at 48 h. (A) Epithelial cells (CD45⁻Epcam⁺MHCII⁺) were sorted, and protein was subjected to I κ B ζ by Western blotting. (B) *REG1* (*ZC3H12A*) was deleted in the human bronchial epithelial cell line by CRISPR-Cas9 ($\Delta REG1$). The cell line was infected with KP (multiplicity of infection, 10) at the indicated time points and assessed for *REG1* (*ZC3H12A*) and I κ B ζ by Western blotting. (C) IL-1 β and GM-CSF by ELISA, and *IL6* and *LCN2* by qPCR. * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA. Data were repeated twice.

others (9–11). *Reg1* has a ubiquitin association domain at the N-terminus, a PIN-like RNase domain along with a conserved CCCH-type Zn finger domain in the middle, and a proline-rich domain at the C-terminus (12). The PIN-like RNase domain is responsible for *Reg1* degrading translationally active client mRNAs by recognizing stem-loop structures in 3' UTRs (13).

In previous work, bone marrow chimera studies revealed that *Reg1* in hematopoietic and nonhematopoietic compartments contributes to susceptibility to KP pneumonia (8). This finding prompted the present study of *Reg1* in lung epithelial cells. The lung epithelium plays a crucial role in KP resistance through the secretion of neutrophil-chemoattractant proteins and antimicrobial peptides (14, 15). Two pathways crucial for KP resistance converge in the lung epithelium, both recognizing and inducing *Reg1*, TLR4, and IL-17R, which are crucial for KP resistance (9, 16). On the basis of this premise, we hypothesized that targeting *Reg1* deletion in AT2 cells would enhance KP resistance by prolonging the half-life of proinflammatory mediators.

We found that lung AT2 cells are highly dynamic during KP infection, and we detected three distinct populations by single-cell RNA sequencing based on canonical gene expression: conventional, inflammatory, and cycling AT2 cells. The importance of different groups of AT2 cells was highlighted in a model of bleomycin-induced lung injury, where AT2 cells enriched in inflammatory genes, named primed AT2 cells, eventually differentiate into damage-associated transient progenitors crucial

for lung regeneration (17). We found a similar subgroup of AT2 cells enriched in inflammatory genes, including *Reg1* (*Zc3h12a*), which we named inflammatory AT2 cells (i-AT2). Ciliated cells also expressed *Reg1* in our dataset, but they were less enriched than AT2 cells. Our data are also supported by publicly available transcriptome information (www.lungmap.net), where *Reg1* is primarily enriched in AT2 cells compared with other epithelial cells. On the basis of these findings, our strategy was to delete *Reg1* (*Zc3h12a*) in AT2 cells.

Although we efficiently deleted *Reg1* in AT2 cells, our findings did not support our hypothesis, because there was no difference in bacterial burden or survival between *WT Reg1* and $\Delta Reg1$ mice. These results differed from our previous publication in which we noted a modest but significant difference in survival between WT and mice with *Reg1* deletion in AT2 cells (8). This difference is due primarily to the increased number of mice per group. In the present study, we included 29 *WT Reg1* mice and 29 $\Delta Reg1$ mice, representing cumulative findings from four independent experiments. The significant increase in mice eliminated the modest significance seen in our previous publication (8).

Would deletion of *Reg1* using a broader epithelial Cre impact KP resistance? The pan-lung epithelial *Nkx2.1*Cre has been used to delete *Reg1* in a model of *Pseudomonas aeruginosa*, with a modest but significant decrease in bacterial burden at 24 h after infection (18). However, survival at day 5 after infection was




FIGURE 4. Reg1 deletion in AT2 cells associates with increased alveolar macrophages.

(A) Total lung tissue was assessed for gene expression of *Nfkbiz*, *Il6*, *Il1b*, *Tnf*, *Cxcl1*, *Cxcl5*, *Ccl2*, and *Csf2* by qPCR at 48 h after KP infection. * $p < 0.05$, unpaired t test. (B) Absolute numbers of alveolar macrophages (CD11c^{hi}CD11b⁻SiglecF^{hi}), neutrophils (CD11b⁺Ly6G^{hi}), recruited monocytes (Cd11b⁺CD11c⁻Ly6G⁻MHCII⁻Ly6C^{hi}) and CD11b⁺ dendritic cells (Ly6G⁻SiglecF⁻CD11c⁺CD11b⁺MHCII⁺) recruited to the lung at 48 h after KP infection. * $p < 0.05$, one-way ANOVA. Data are representative of two different experiments.

unchanged between the WT and conditional KO mice. Using a pan-epithelial Cre would not add a significant difference in survival, because Reg1 is mostly expressed in AT2 cells. However, a definitive experiment needs to be performed to rule out that possibility.


Interestingly, other nonhematopoietic cells, such as lung endothelial and mesenchymal cells, express higher levels of Reg1 than lung epithelial cells (www.lungmap.net). Thus, deleting Reg1 in lung endothelial or mesenchymal cells may increase KP resistance more than in epithelial cells. Lung endothelial cells are highly heterogeneous, and recent infection models have started to unravel different subtypes of lung endothelial cells during lung injury (19). Another group of nonhematopoietic cells that express high levels of Reg1 is lung mesenchymal cells. Very few studies have assessed these cells in the context of KP infection. Lung mesenchymal cells have phagocytic capacity and

anti-inflammatory activity (20). Thus, exploration of whether deleting Reg1 in these cells would protect or predispose to KP infection has yet to be done.

Our in vivo and in vitro data showed enhanced *Nfkbiz*, which encodes I κ B ζ . KP-infected Δ*REG1* human bronchial epithelial cells significantly induce I κ B ζ ; this likely results from *Nfkbiz* mRNA stabilization, which is predicted to have two stem-loop structures in the 3' UTR for Reg1-mediated mRNA decay (13). *Nfkbiz* is induced by TLR4 signaling and IL-17R signaling (9, 21). *Nfkbiz* is induced rapidly, and it is considered a primary response gene (22). It mediates the activation of secondary response genes such as *Il6*, *Il12*, *Ccl2*, and *Csf2*, which are activated at later time points than *Nfkbiz* and are not induced in *Nfkbiz*^{-/-} cells (21, 23). Furthermore, *Il6* also has a stem-loop in the 3' UTR that Reg1 recognizes for mRNA degradation. Thus, our findings suggest that *Nfkbiz* and *Il6* expression are

FIGURE 5. Reg1 deletion in AT2 cells does not affect KP resistance.

(A) Lung and (B) spleen KP burden in Δ Reg1 or WT Reg1 mice up to 72 h postinfection. Each dot and circle represent a mouse. One-way ANOVA, ns, not significant, $p > 0.05$. (C) Survival of Δ Reg1 or WT Reg1 littermates was assessed up to 7 d after infection ($n = 29$ mice/group). (D) Weight loss was assessed at the indicated time points ($n = 29$ mice/group). Data are pooled from four experiments.



locally stabilized due to conditionally deleting Reg1 in AT2 cells.

There was no difference in chemokine expression such as *Cxcl1*, *Cxcl5*, or *Ccl2*, and, accordingly, the recruitment of neutrophils and inflammatory monocytes was similar between groups. However, alveolar macrophages were higher in Δ Reg1 mice than in controls. Because the alveolar macrophages have an intact Reg1 protein, we speculate that a prosurvival factor is being secreted in higher amounts from the Δ Reg1 AT2 cells than the WT Reg1 and acting on alveolar macrophages. One possible prosurvival factor is GM-CSF, encoded by *Csf2* and enhanced by *Nfkbiz*. Although total lung GM-CSF was similar between WT Reg1 and Δ Reg1 mice (Supplemental Fig. 1F), more in-depth functional in vivo experiments and loss-of-function studies are needed to know that for sure.

Notably, the effect of deleting Reg1 in AT2 cells may be offset by other RNA-binding proteins, particularly Roquin 1/2 (RC3H1/2), which share the same 3' UTR target transcripts for degradation as Reg1 (13). Furthermore, at least in T cells, Reg1 and Roquin cooperate to target the degradation of several proinflammatory transcripts, which is vital to keep autoimmunity in check (24, 25). Would concomitant deletion of Roquin1/2 and Reg1 in AT2 cells have a different outcome? Would the host eradicate KP at the cost of lung injury? These are areas that have not been explored yet.

Overall, the immune system has evolved to balance the vital effects of antimicrobial effector functions with the potential for causing collateral tissue damage. Consequently, activating every immune signaling pathway is accompanied by negative feedback signaling events designed to mitigate inflammation (26, 27). However, allowing localized, heightened inflammation to treat a life-threatening condition may be clinically advantageous. Releasing inflammatory “brakes,” ideally in a limited fashion, may be

helpful in the context of severe infections such as bacterial pneumonia, and exploring the potential role of Reg1 in other lung structural cells could, in principle, represent a valuable target to achieve this goal.

DISCLOSURES

The authors declare no conflicts of interest.

REFERENCES

- Magill, S. S., J. R. Edwards, W. Bamberg, Z. G. Beldavs, G. Dumyati, M. A. Kainer, R. Lynfield, M. Maloney, L. McAllister-Hollod, J. Nadle, et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. 2014. Multistate point-prevalence survey of health care-associated infections. *N. Engl. J. Med.* 370: 1198–1208.
- Weiner, L. M., A. K. Webb, B. Limbago, M. A. Dudeck, J. Patel, A. J. Kallen, J. R. Edwards, and D. M. Sievert. 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. *Infect. Control Hosp. Epidemiol.* 37: 1288–1301.
- Parrott, A. M., J. Shi, J. Aaron, D. A. Green, S. Whittier, and F. Wu. 2021. Detection of multiple hypervirulent *Klebsiella pneumoniae* strains in a New York City hospital through screening of virulence genes. *Clin. Microbiol. Infect.* 27: 583–589.
- Gu, D., N. Dong, Z. Zheng, D. Lin, M. Huang, L. Wang, E. W. Chan, L. Shu, J. Yu, R. Zhang, and S. Chen. 2018. A fatal outbreak of ST11 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* in a Chinese hospital: a molecular epidemiological study. *Lancet Infect. Dis.* 18: 37–46.
- Zhang, Y., J. Zeng, W. Liu, F. Zhao, Z. Hu, C. Zhao, Q. Wang, X. Wang, H. Chen, H. Li, et al. 2015. Emergence of a hypervirulent carbapenem-resistant *Klebsiella pneumoniae* isolate from clinical infections in China. *J. Infect.* 71: 553–560.

6. Turton, J. F., Z. Payne, A. Coward, K. L. Hopkins, J. A. Turton, M. Doumith, and N. Woodford. 2018. Virulence genes in isolates of *Klebsiella pneumoniae* from the UK during 2016, including among carbapenemase gene-positive hypervirulent K1-ST23 and 'non-hypervirulent' types ST147, ST15 and ST383. *J. Med. Microbiol.* 67: 118–128.
7. Kamau, E., E. L. Ranson, A. T. Tsan, E. S. Bergmann-Leitner, O. B. Garner, and S. Yang. 2022. Clinical and genomic characterization of hypervirulent *Klebsiella pneumoniae* (hvKp) infections via passive surveillance in Southern California, 2020–2022. *Front. Microbiol.* 13: 1001169.
8. Trevejo-Núñez, G., B. Lin, L. Fan, F. E. Y. Aggor, P. S. Biswas, K. Chen, and S. L. Gaffen. 2022. Regnase-1 deficiency restrains *Klebsiella pneumoniae* infection by regulation of a type I interferon response. *MBio* 13: 03792–21.
9. Garg, A. V., N. Amatya, K. Chen, J. A. Cruz, P. Grover, N. Whibley, H. R. Conti, G. Hernandez Mir, T. Sirakova, E. C. Childs, et al. 2015. MCP1P1 endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation. *Immunity* 43: 475–487.
10. Matsushita, K., O. Takeuchi, D. M. Standley, Y. Kumagai, T. Kawagoe, T. Miyake, T. Satoh, H. Kato, T. Tsujimura, H. Nakamura, and S. Akira. 2009. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. *Nature* 458: 1185–1190.
11. Liang, J., Y. Saad, T. Lei, J. Wang, D. Qi, Q. Yang, P. E. Kolattukudy, and M. Fu. 2010. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. *J. Exp. Med.* 207: 2959–2973.
12. Yokogawa, M., T. Tsushima, N. N. Noda, H. Kumeta, Y. Enokizono, K. Yamashita, D. M. Standley, O. Takeuchi, S. Akira, and F. Inagaki. 2016. Structural basis for the regulation of enzymatic activity of regnase-1 by domain-domain interactions. *Sci. Rep.* 6: 22324.
13. Mino, T., Y. Murakawa, A. Fukao, A. Vandenbon, H. H. Wessels, D. Ori, T. Uehata, S. Tartey, S. Akira, Y. Suzuki, et al. 2015. Regnase-1 and roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. *Cell* 161: 1058–1073.
14. Chen, K., T. Eddens, G. Trevejo-Nunez, E. E. Way, W. Elsegeiny, D. M. Ricks, A. V. Garg, C. J. Erb, M. Bo, T. Wang, et al. 2016. IL-17 receptor signaling in the lung epithelium is required for mucosal chemokine gradients and pulmonary host defense against *K. pneumoniae*. *Cell Host Microbe* 20: 596–605.
15. Chan, Y. R., J. S. Liu, D. A. Pociask, M. Zheng, T. A. Mietzner, T. Berger, T. W. Mak, M. C. Clifton, R. K. Strong, P. Ray, and J. K. Kolls. 2009. Lipocalin 2 is required for pulmonary host defense against *Klebsiella* infection. *J. Immunol.* 182: 4947–4956.
16. Iwasaki, H., O. Takeuchi, S. Teraguchi, K. Matsushita, T. Uehata, K. Kuniyoshi, T. Satoh, T. Saitoh, M. Matsushita, D. M. Standley, and S. Akira. 2011. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. *Nat. Immunol.* 12: 1167–1175.
17. Choi, J., J. E. Park, G. Tsagkogeorga, M. Yanagita, B. K. Koo, N. Han, and J. H. Lee. 2020. Inflammatory signals induce AT2 cell-derived damage-associated transient progenitors that mediate alveolar regeneration. *Cell Stem Cell* 27: 366–382.e7.
18. Nakatsuka, Y., A. Vandenbon, T. Mino, M. Yoshinaga, T. Uehata, X. Cui, A. Sato, T. Tsujimura, Y. Suzuki, A. Sato, et al. 2018. Pulmonary regnase-1 orchestrates the interplay of epithelium and adaptive immune systems to protect against pneumonia. *Mucosal Immunol.* 11: 1203–1218.
19. Niethamer, T. K., C. T. Stabler, J. P. Leach, J. A. Zepp, M. P. Morley, A. Babu, S. Zhou, and E. E. Morrisey. 2020. Defining the role of pulmonary endothelial cell heterogeneity in the response to acute lung injury. *eLife* 9: e53072.
20. Barkauskas, C. E., M. J. Crouce, C. R. Rackley, E. J. Bowie, D. R. Keene, B. R. Stripp, S. H. Randell, P. W. Noble, and B. L. Hogan. 2013. Type 2 alveolar cells are stem cells in adult lung. *J. Clin. Invest.* 123: 3025–3036.
21. Yamamoto, M., S. Yamazaki, S. Uematsu, S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Kuwata, O. Takeuchi, K. Takeshige, et al. 2004. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. *Nature* 430: 218–222.
22. Kayama, H., V. R. Ramirez-Carrozzi, M. Yamamoto, T. Mizutani, H. Kuwata, H. Iba, M. Matsumoto, K. Honda, S. T. Smale, and K. Takeda. 2008. Class-specific regulation of pro-inflammatory genes by MyD88 pathways and IkappaBzeta. [Published erratum appears in 2015 *J. Biol. Chem.* 290: 4815.] *J. Biol. Chem.* 283: 12468–12477.
23. Hildebrand, D. G., E. Alexander, S. Hörber, S. Lehle, K. Obermayer, N. A. Münck, O. Rothfuss, J. S. Frick, M. Morimatsu, I. Schmitz, et al. 2013. IκBζ is a transcriptional key regulator of CCL2/MCP-1. *J. Immunol.* 190: 4812–4820.
24. Behrens, G., S. L. Edelman, T. Raj, N. Kronbeck, T. Monecke, E. Davydova, E. H. Wong, L. Kifinger, F. Giesert, M. E. Kirmaier, et al. 2021. Disrupting roquin-1 interaction with regnase-1 induces autoimmunity and enhances antitumor responses. *Nat. Immunol.* 22: 1563–1576.
25. Behrens, G., and V. Heissmeyer. 2022. Cooperation of RNA-binding proteins - a focus on roquin function in T cells. *Front. Immunol.* 13: 839762.
26. Carpenter, S., E. P. Ricci, B. C. Mercier, M. J. Moore, and K. A. Fitzgerald. 2014. Post-transcriptional regulation of gene expression in innate immunity. *Nat. Rev. Immunol.* 14: 361–376.
27. Li, X., R. Bechara, J. Zhao, M. J. McGeachy, and S. L. Gaffen. 2019. IL-17 receptor-based signaling and implications for disease. *Nat. Immunol.* 20: 1594–1602.